Skip to main content
You have permission to edit this article.
Edit
Psychedelic drugs will follow pot’s path to legalization, by Noah Feldman

Psychedelic drugs will follow pot’s path to legalization, by Noah Feldman

  • 1
{{featured_button_text}}

Here come the psychedelics. A striking new study published in Nature Medicine argues that MDMA-assisted psychotherapy represents “a potential breakthrough treatment” for post-traumatic stress disorder. Other studies are in the works considering the potential therapeutic applications of psilocybin (the active ingredient in magic mushrooms), LSD and cannabinoids. These follow well-received books on different forms of psychedelic use by such mainstream figures as food writer Michael Pollan, novelist Ayelet Waldman and columnist Ezra Klein.

If you’re a reader of mainstream news media, expect to hear more and more about this topic over the next few years. And even if you are a buttoned-down rule-follower, expect to hear an increasing number of your friends and acquaintances expressing interest in psychedelics — and maybe even experimenting with them.

None of this is happenstance. It’s the product of a sophisticated, loosely coordinated effort to encourage the gradual legalization of psychedelics via medicalization and cultural normalization.

The movement doesn’t seem to be motivated mainly by money, although there is doubtless money to be made. Instead, the psychedelic community is broadly motivated by a genuine belief that these substances — “medicines,” as many refer to them — contribute meaningfully to human well-being and are not addictive or dangerous when properly used.

It would take a book — or at least a series of columns — to chart even a smattering of the fascinating aspects of this complex social process. But one question deserves to be answered first: Will the legalization effort succeed? I think the answer is yes.

There’s no doubt that legalization faces challenges from prohibitions put in place during the Nixon and Reagan administrations. But the combination of medicalized research and cultural mainstreaming is potent. The advocates are for the most part white, well-educated and well-off. And they are using science to make a persuasive case that the old arguments against psychedelics are obsolete, grounded as they were in a fundamental fear of the experience of altered consciousness.

Start with the medicalization approach, which represents a stark contrast to the way psychedelics entered American awareness in the 1960s. In that period, the attraction of psychedelics was primarily their capacity to expand consciousness. Think of Tom Wolfe’s classic “Electric Kool-Aid Acid Test.” But today’s psychedelic activists — although they may themselves be motivated by something similar — focus their public message on the therapeutic use of psychedelics. Psychedelics are depicted as medicines capable of bringing healing, particularly for hard-to-treat conditions like severe depression, PTSD and schizophrenia.

Seen from the standpoint of legal strategy, this makes sense. In contemporary American public life, it’s difficult to stand up and say that our collective consciousness is in serious need of expansion. (What, exactly, would that even mean?) Yet we all know that even as we have gotten more sophisticated about the prevalence and reality of various forms of mental illness, the professions of psychiatry and psychology have struggled to provide adequate treatments. If psychedelics can be shown to work in controlled scientific studies, that will create a powerful argument for their legal, medical use.

What distinguishes the movement to legalize psychedelics is that it is substantially more elite than the movement surrounding pot, a drug that crosses economic and cultural lines. The Columbia University psychologist Carl Hart, author of a thought-provoking new book called “Drug Use for Grownups,” expresses some frustration with what he depicts as the desire of white, upper-middle-class psychedelic activists to differentiate their practices from the use of other drugs by implicitly nonwhite and poor “addicts.” If opioids are perceived as the drug of the white poor, as crack cocaine was depicted in previous decades as the drug of poor Black people, today’s psychedelic medicines are likely to benefit from being seen as the drugs of wealthy coastal cultural elites.

It will take time for psychedelics to go from illegal to medical-use-only to broadly legal. But there is overwhelming reason to believe that this process will occur. Repackaged as therapeutic and elite, psychedelics may be the medicine of our time.

Catch the latest in Opinion

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.

Related to this story

Most Popular

Maybe it was the house fire near a homeless encampment off Main Street in Venice that killed a beloved family dog. Maybe it was the blaze that leaped from one of an estimated 223 tents on the Venice Boardwalk and destroyed a commercial building on Ocean Front Walk. Or maybe it’s the surge in violent crime, the rash of stolen bicycles or videos of RVs dumping their sewage in the streets. But ...

No wonder the Biden administration chose to release their 2022 budget just before a long holiday weekend. It’s a common Washington practice for releasing news that officials hope will go unnoticed. Biden’s defense budget offers little to improve any of the uniformed services, but it would absolutely devastate the readiness of the U.S. Army. The Army’s 2022 budget needed to be $180 billion just ...

Tobacco addiction is not a choice. Research shows nearly 70 percent of people who smoke want to quit and about half of people who smoke make a quit attempt every year. The tobacco industry knows it must keep customers addicted, and companies use insidious approaches to maintain a customer base. Menthol and flavors have played a major role in the addiction equation. The U.S. Food and Drug ...

If China hopes to avert a fall in its population by raising the maximum number of children per mother from two to three, it’s going to have its work cut out. That’s because declining fertility, once started, tends to be an inexorable force that few nations have managed to arrest, let alone reverse. Of the 85 countries where fertility had fallen to less than 2.1 births per woman in 2009 — the ...

The war against smokers continues, as the FDA will move to ban menthol cigarettes. From the initial bans on smoking indoors in the late 1990s, to the current war on vaping, nicotine users have been increasingly marginalized. And they’re particularly discriminated against by the wealthy and ruling class, especially because smoking has become more concentrated in lower-income people. Now, the ...

A veteran with a fever and hacking cough that suggest a possible coronavirus infection tries to make a doctor’s appointment, only to be turned away by a receptionist who personally decides the would-be patient can’t see a physician. A former service member and sexual assault survivor at risk of suicide is denied access to mental health services by a bureaucratic gatekeeper stationed at the ...

Even if we never learn whether COVID-19 escaped from a lab or jumped to humans from animals, the public is entitled to a closer look at what’s going on in virology labs. Some scientists worry that laboratory scientists are getting too little oversight on projects that could potentially start pandemics. Others worry about the global proliferation of labs that work with dangerous viruses and ...

The best local coverage, unlimited

Sign up for a digital subscription to The Press of Atlantic City now and take advantage of a great offer.

LEARN MORE

Get up-to-the-minute news sent straight to your device.

Topics

Breaking News